Latest Corporate & Commercial Updates

Latest Press releases

A new milestone for Immunoscore® in the UK

Five major private medical insurances in the UK cover Immunoscore® test for all their patients with localised colon...

 Read more

OSE Immunotherapeutics and HalioDx Collaborate to Perform Immune Biomarker Exploratory Work during Atalante 1 Phase 3 Clinical Trial of Tedopi® in Non-Small Cell Lung Cancer

OSE Immunotherapeutics (ISIN: FR0012127173; Mnémo: OSE), a clinical-stage biotechnology company focused on developing...

 Read more

HalioDx and Kite, a Gilead company, to extend strategic collaboration beyond Lymphoma

Kite to Leverage HalioDx’s Immunoscore® Solutions to Understand Tumor Microenvironment and Guide Cancer Cell Therapies...

 Read more

Immunoscore® to support Immuno-oncology and microbiome research within the ONCOBIOME consortium

  • A 15M€ European granted consortium led by Laurence Zitvogel from Gustave Roussy in Villejuif.
  • HalioDx task is to link...
 Read more

Jérôme Galon received the European Inventor Award 2019 for Immunoscore®

HalioDx is very proud to share this great news!

 Read more

Immunoscore® demonstrates clinical utility in stage III colon cancer

  • Positive results on Immunoscore® in stage III colon cancer patients treated with oxaliplatin in the prospective IDEA...
 Read more

IMMUNOSCORE® in Colon Cancer

HalioDx Signs an Exclusive Agreement with Genecast to Make Immunoscore® Available in China

HalioDx SAS, an immuno-oncology company pioneering the immunological diagnosis of cancers, today announced that it has...

 Read more

IMMUNOSCORE® in Colon Cancer

Immunoscore® CR for Immunotherapies at AACR 2019

  • Results from immunotherapy based clinical trials including HalioDx’s Immunoscore®CR  and Immunosign®, will be...
 Read more

IMMUNOSCORE® in Colon Cancer

See more Press releases